Search results
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 5 hours agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor ...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks· 7 days agoFree Report) incurred a first-quarter 2024 loss of 54 cents per share, which matched the Zacks Consensus Estimate. Total revenues amounted to $172.3 million in the reported quarter, beating ...
Kids and Anti-Obesity Meds: Real-World Challenges
Medscape· 4 days agoThe ability to provide adolescents with highly effective anti-obesity medications that now carry approvals from the US Food and Drug Administration (FDA)...
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and...
WTNH-TV New Haven· 5 days agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder
Journal of the American Medical Association· 6 days agoThis stepped-wedge cluster trial evaluates the effectiveness of a rapid 5- to 7-day initiation of extended-release naltrexone compared with the standard 12- to 14-day procedure among individuals with opioid use disorder.
Your Costa cappuccino could contain three times more caffeine than one from Cafe Nero - how can...
Cycling Weekly· 4 days ago“Many of the team have their own Aeropress, and Rigoberto Urán even owns a coffee farm in Colombia...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 4 days agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoData from this Phase 2 trial, along with data from the expanded Phase 1 cohort and a real-world evidence data set, support our anticipated BLA filing by...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript May 8, 2024 Y-mAbs...
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoWe are currently in Part A. and...encouraged by what we've seen. So far to date, no patients in the trial have experienced any dose-limiting toxicities and there have been ...
